On April 28, 2026, the trial registry updated the status of a study involving buserelin. The trial, titled "A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer," is registered under identifier NCT07553988. It is a Phase 2 study. Its current status is listed as active, not recruiting. This status indicates that participant enrollment is no longer ongoing but the study has not concluded. No results have been posted for this trial as of the date of this update. The study focuses on dose-finding in patients with metastatic castration-resistant prostate cancer. Buserelin, an approved compound, is referenced in connection with this trial record. No efficacy or safety outcomes are included in this update. Readers should not interpret this status change as an indication of trial results or conclusions about treatment effect. Further updates may be issued as the trial progresses through its stages. For general background on buserelin, readers can consult the compound overview.
Buserelin-Related Trial NCT07553988 Now Active, Not Recruiting
See the full buserelin overview
Source: https://clinicaltrials.gov/study/NCT07553988